{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:48:02Z","timestamp":1758905282070},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":4368,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1994,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A SCID mouse model of human T\u2010ALL has been used to determine the <jats:italic>in vivo<\/jats:italic> therapeutic efficacy of two anti\u2010CD7\u2010saporin immunotoxins constructed with either a hindered (HB2\u2010SMPT\u2010Sap) or non\u2010hindered (HB2\u2010SPDP\u2010Sap) disulphide bond between antibody and saporin. Groups of 10 SCID mice were injected intravenously (i.v.) with 2 \u00d7 10<jats:sup>6<\/jats:sup> human T\u2010ALL HSB\u20102 cells followed seven days later by i.v. injection with either a single dose or with 3 doses of HB2\u2010SPDP\u2010Sap or HB2\u2010SMPT\u2010Sap given on alternate days. Control groups received equivalent sham injections of PBS or molar equivalent amounts of unconjugated HB2 antibody + saporin. Animals receiving a single dose of HB2\u2010SMPT\u2010Sap showed better survival than animals receiving a single dose of HB2\u2010SPDP\u2010Sap but the difference was not shown to be significant by log\u2010rank analysis. When given as a triple dose both immunotoxins performed similarly. Comparison of single\u2010dose with triple\u2010dose IT therapy revealed that the therapeutic effect of a triple dose of HB2\u2010SPDP\u2010Sap was significantly better than that of single dose, but this was not the case with HB2\u2010SMPT\u2010Sap. Pharmacokinetic studies of HB2\u2010SPDP\u2010Sap and HB2\u2010SMPT\u2010Sap in normal and HSB\u20102 leukaemia bearing SCID mice failed to reveal any difference in clearance rates for these two IT's. We conclude from these studies that there is no therapeutic advantage to be gained from constructing the HB2\u2010Sap IT with a hindered disulphide bond in this particular model of human T\u2010ALL.<\/jats:p>","DOI":"10.1002\/ijc.2910580317","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:23:06Z","timestamp":1171930986000},"page":"407-414","source":"Crossref","is-referenced-by-count":17,"title":["Therapy of human T\u2010cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti\u2010CD7\u2010saporin immunotoxins containing hindered or non\u2010hindered disulphide cross\u2010linkers"],"prefix":"10.1002","volume":"58","author":[{"given":"David J.","family":"Flavell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice A.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sopsamor N. U.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(79)90504-4"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"A Phase\u2010I study of an anti\u2010CD22\u2010deglycosylated Ricin\u2010A\u2010chain immunotoxin in the treatment of B\u2010cell lymphomas resistant to conventional therapy","volume":"82","author":"Amlot P. L.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.135.5.2911","article-title":"Evidence that lymphokine\u2010activated killer cells and natural killer cells are distinct based on an analysis of congenially immunodeficient mice","volume":"135","author":"Andriole G. L.","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_5_1","first-page":"947","article-title":"Effect of chemical deglycosylation of Ricin\u2010A\u2010chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of Ricin\u2010A\u2010chain and anti\u2010Thy 1.1 antibody","volume":"47","author":"Blakey D. C.","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_1_6_1","first-page":"3056","article-title":"Efficacy of an anti\u2010CD7 Ricin\u2010A\u2010chain immunoconjugate in a novel murine model of human T\u2010cell leukaemia","volume":"82","author":"Fishwild D. M.","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.291"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.1016\/S0021-9258(17)38981-0","article-title":"Purified immunotoxins that are reactive with human lymphoid cells. MAbs conjugated to the RIPs gelonin and PAP","volume":"260","author":"Lambert J. M.","year":"1983","journal-title":"J. boil. Chem."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.52"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2160617"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.9.953"},{"key":"e_1_2_1_13_1","first-page":"151","article-title":"An immunotoxin composed of monoclonal anti\u2010Thy 1.1 antibody and a ribosome\u2010inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo","volume":"75","author":"Thorpe P. E.","year":"1985","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_14_1","first-page":"5924","article-title":"New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo","volume":"47","author":"Thorpe P. E.","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","first-page":"6396","article-title":"Improved anti\u2010tumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulphide linkages","volume":"48","author":"Thorpe P. E.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03329.x"},{"key":"e_1_2_1_17_1","first-page":"4032","article-title":"Phase\u2010I immunotoxin trial in patients with B\u2010cell lymphoma","volume":"81","author":"Vitetta E. S.","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90041-I"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910580317","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910580317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T17:00:56Z","timestamp":1698166856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910580317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,8]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,8]]}},"alternative-id":["10.1002\/ijc.2910580317"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910580317","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,8]]}}}